All News

A study found that CT scans of visceral fat had the highest predictive performance of incident diabetes.

From expanding vaccination coverage to battling with PBMs, the community pharmacist has the ability to promote change like never before.

A study found that test products purchased from illegal online pharmacy operations had lower purity levels and significantly more semaglutide content than what was advertised on the label.

Finerenone (Kerendia) was previously approved in 2021 to reduce the risk of cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, sustained eGFR decline, and end-stage kidney disease in adult patients with chronic kidney disease associated with type 2 diabetes.

As clinical research continues, investigators are learning more about how GLP-1 drugs modify cardiovascular risks.

Lifestyle changes—including eating fruits, vegetables, and whole grains—can help patients, especially those with diabetes or hypertension, improve outcomes.

In case you missed it, this week we had news about CVS in the spotlight of PBM reform, landmark FDA approvals in synovial sarcoma, liraglutide for dementia, and more.

GLP-1 therapies are being evaluated to treat cardiovascular and kidney diseases in individuals with overweight or obesity.

These therapies are highly beneficial, but can come with a host of gastrointestinal adverse effects that patients may not be prepared to manage alone.

Check out important updated from the FDA for the week of July 29.

Researchers aimed to discover whether pharmacist-led delivery of oral anticoagulation therapy can lead to an increase in stroke risk reduction for patients with actionable atrial fibrillation.

The technology from Diakonos Oncology initiates a natural immune response that targets and eliminates cancer cells by activating cytotoxic TH1 cell signaling pathways.

Afami-cel is the first new treatment for synovial sarcoma in more than 10 years, ending a long-standing therapeutic gap.

Liraglutide slowed the loss of volume in critical brain regions and cognitive decline in patients with mild Alzheimer's dementia.

Pharmacists should be knowledgeable about the symptoms of chemical peel irritation to effectively advise patients.

In 3 Phase 3 trials, elinzanetant reduced the frequency and severity of moderate to severe vasomotor symptoms, and improved sleep disturbances.

Researchers aimed to address the association of all-cause dementia risk and 3 separate chronicities of anxiety.

Anisha Patel, PharmD, a pharmacist turned podcast host, shares insights on leveraging all the opportunities pharmacy has to offer to build a diverse and rewarding career.

Catch up on important immunization news from the month of July.

The investigational oral, selective NaV1.8 pain signal inhibitor from Vertex Pharmaceuticals demonstrated a favorable benefit/risk profile in 3 phase 3 trials.

Researchers aimed to address the change in trust individuals exhibited regarding US physicians and hospitals during the COVID-19 pandemic.

Catch up on important diabetes news from the month of July.

Catch up on important pain management news from the month of July.

CVS Caremark and the State of Illinois settled a lawsuit due to the company’s failure to pay contracted rebates.

The new FDA-approved presentation will be the company’s third 505(b)(2) injectable added in 2024, expected to launch in the third quarter.

Catch up on important dermatology news from the month of July.

Researchers analyzed the prominence of opioid and methadone prescriptions for hospitalized newborns with substantial morbidities.

Check out this list of our top 10 most read stories from July 2024.